Marc Arthur Loko
- Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohortMarc Arthur Loko
Universite Bordeaux, ISPED, Centre INSERM U897 Epidemiologie Biostatistique, F 33000 Bordeaux, France
Antivir Ther 17:1335-43. 2012..The aim of this study was to describe changes in repeated liver stiffness (LS) measurements and to assess the determinants of increase in LS in HIV-HCV-coinfected patients...
- Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)Dominique Salmon-Ceron
Unité de maladies infectieuses, Pôle Médecine, Hopital Cochin, Paris, France
BMC Health Serv Res 12:59. 2012..Treatment for the hepatitis C virus (HCV) may be delayed significantly in HIV/HCV co-infected patients. Our study aims at identifying the correlates of access to HCV treatment in this population...
- The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010Marc Arthur Loko
INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
BMC Infect Dis 10:303. 2010..The ANRS CO 13 HEPAVIH cohort was set up to explore these critical questions.To describe the cohort aims and organization, monitoring and data collection procedures, baseline characteristics, as well as follow-up findings to date...
- Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?Pascale Trimoulet
Laboratoire de Microbiologie Fondamentale et Pathogénicité UMR 5234, Centre Hospitalier Universitaire CHU et Université Bordeaux Ségalen, Hopital Pellegrin, Bordeaux, France
J Virol Methods 181:131-3. 2012..0001). This study shows that using the same assay in multicenter trials and cohorts is still relevant due to inter-assay differences observed in HCV plasma load measurements...
- Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort)Fabienne Marcellin
INSERM, UMR912 SESSTIM, Marseille, France
Addiction 108:1250-8. 2013..Studying alcohol abuse impact, as measured by physicians' perceptions and patients' self-reports, on HIV virological rebound among patients chronically co-infected with HIV and hepatitis C virus (HCV)...
- Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral responseFirouzé Bani-Sadr
aUnité des Maladies Infectieuses et Tropicales, Hopital Robert Debre, université Champagne Ardenne, Reims bINSERM, ISPED, Centre INSERM U897 Epidemiologie Biostatistiques, Bordeaux cINSERM, U912 SE4S Université Aix Marseille, IRD, UMR S912 ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d Azur, Marseille dService des Maladies Infectieuses et Tropicales, Groupe Hospitalier Necker Enfants Malades, AP HP, Paris eService des Maladies Infectieuses et Tropicales, Groupe Hospitalier Avicenne, AP HP, Bobigny fService des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard gService des Maladies Infectieuses et Tropicales, Hopital Cochin, APHP Université Paris Descartes, Paris, France
AIDS 28:1155-60. 2014..The impact of hepatitis C virus (HCV)-related characteristics such as genotype, viral load or liver fibrosis on the chances of achieving sustained HIV suppression in coinfected patients is not fully documented...
- Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine CohortDidier Neau
Fédération des Maladies Infectieuses et Tropicales, Centre Hospitalo Universitaire, Hopital Pellegrin, Bordeaux, France
J Acquir Immune Defic Syndr 45:168-73. 2007..The prevalence and factors associated with hepatic steatosis are not well defined in HCV-HIV-coinfected patients...
- Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohortFabienne Marcellin
INSERM, UMR912 SESSTIM, 13006, Marseille, France
Expert Rev Gastroenterol Hepatol 8:351-8. 2014..This article documents the main lessons learned to date from the HEPAVIH data and published literature, while describing research prospects and needs requiring further investigation in the field of patient-reported outcomes. ..
- Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohortMarc Arthur Loko
INSERM, U593, Bordeaux, France
Am J Gastroenterol 103:1973-80. 2008..Although an increasing number of noninvasive fibrosis markers are available in HCV-monoinfected patients, data on the performance of these tests in HIV-HCV-coinfected patients are lacking...
- Decreasing incidence of pregnancy by decreasing CD4 cell count in HIV-infected women in Côte d'Ivoire: a 7-year cohort studyMarc Arthur Loko
INSERM U 593, Universite Victor Segalen, Bordeaux 2, Bordeaux, France
AIDS 19:443-5. 2005..This has consequences in terms of scaling-up strategies for highly active antiretroviral therapy (HAART). Women who need HAART will be less likely than those who do not to be recruited into prenatal care facilities...